AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05186584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION
Description: Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk.
Study NCT05186584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAITLAND'S LATERAL MOBILIZATION
Description: Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
Study NCT01691417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Sequntial Pnumatic Compression Leg Sleeves
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: Tricaprilin formulated as AC-1202
Study NCT05283811 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NEUROPACE RNS SYSTEM
Description: This device is indicated as a therapy in reducing the frequency of seizures in individuals
Study NCT05283811 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMU
Description: Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-01
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-02
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-03
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-04
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-05
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-06
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-07
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-08
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-09
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-010
Description: Tricaprilin Formulation
Study NCT05028114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-OLE-P
Description: Placebo to tricaprilin formulation
Study NCT04455620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT151
Description: intravenous
Study NCT05901909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients
Description: Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
Study NCT05417295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inflating air into the bronchial cuff before changing position
Description: Inflating air into the bronchial cuff before or after changing position
Study NCT05417295 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inflating air into the bronchial cuff after changing position
Description: Inflating air into the bronchial cuff after changing position
Study NCT05470244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy and Intra-venous analgesic regimen
Description: ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
Study NCT05470244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen
Description: High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
Study NCT04999943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
Study NCT04999943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC vaccine
Description: EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
Study NCT06148103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Patients who received Dexmedetomodine
Description: 1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
Study NCT06148103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: patients who received propofol-fentanyl
Description: Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
Study NCT05679115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle tool
Description: Regular use of the digital Lifestyle tool
Study NCT05707416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)
Description: The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
Study NCT05707416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group B
Description: Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
Study NCT06484296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test.
Study NCT05232747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test
Study NCT04484727 — intervention group
Intervention type: OTHER
Intervention: PEEP-step method
Description: By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.
Study NCT04148781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Description: Fampridine-SR 10 mg twice daily for 8 weeks
Study NCT05863468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArchSinus implantation
Description: Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
Study NCT04912427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab is supplied by Sanofi.
Study NCT04912427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is commercially available.
Study NCT04912427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is commercially available.
Study NCT06246695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Oral Jaktinib 100 mg for 1 day
Study NCT06246695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: Oral Itraconazole 200 mg for 9 day
Study NCT06246695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin Capsules
Description: Oral Rifampicin 600 mg for 11 day
Study NCT05679089 — intervention group
Intervention type: DEVICE
Intervention: early detection test
Description: Blood collection and early detection testing
Study NCT05223075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine local anethesia with vasoconstrictor
Description: buccal infiltration only of articaine local anethesia during extraction of lower anterior teeth
Study NCT05223075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine local anethesia with vasoconstrictor
Description: buccal infiltration only of lidocaine local anethesia during extraction of lower anterior teeth
Study NCT06106139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strict ketogenic diet group
Description: the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.
Study NCT06106139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclic ketogenic diet group
Description: the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group.
Study NCT06106139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Autonomous ketogenesis group
Description: Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600\~2400 kcal.
Study NCT04672408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: His bundle pacing
Description: Pacing with capture of the His bundle
Study NCT04672408 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Right ventricular pacing
Description: Pacing from the right ventricular lead (septal or apical)
Study NCT05382546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
Study NCT05748574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sleep Well Sachet
Description: Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
Study NCT05880108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-weeks of Weight Loss
Description: Participants will be asked to participate in a 1x/week center-based nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for 12 weeks.
Study NCT05880108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-weeks of Weight Stability
Description: Participants will be asked to participate in a 1x/week center-based health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for 12 weeks.
Study NCT05202054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness stress reduction program
Description: Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
Study NCT04478136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test of factor levels
Description: Blood draw from central line to check coagulation factors
Study NCT06450847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soleus Muscle Push Up Exercise
Description: Members will be asked to do the SPUs for 270 minutes/day for most days of the week (minimum 5 days) for 3 months:~1. Begin seated on a bench or chair so knees form a 90-degree angle with feet flat on the floor and toes pointed forward. Keep spine straight and shoulders back (not hunched or rounded forward).~2. Using a slow and controlled tempo, push toes into the floor and lift heels off the ground.~3. Hold for one to two seconds, pushing down on the balls of feet. Keep your thigh muscles relaxed.~4. Slowly lower heels and return to start. That's 1 rep. Without shoes Educational session will be given before the intervention time WhatsApp messages will be sent 1-2 times/day to remind the participants to continue doing the exercise and ascertain compliance. Also, the participants are required to daily fill logbook about the duration (in minutes) of the SPU that they did.
Study NCT06450847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other Exercise
Description: Participants will be asked to continue their regular lifestyle
Study NCT06269094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: CGM use for 6 weeks during virtual focus groups
Study NCT06322238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: PGx panel test
Description: In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mankato), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.
Study NCT06322238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PGx panel test
Description: In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mankato), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.
Study NCT06697782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
Study NCT06697782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron 8mg
Description: Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
Study NCT06697782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant 125 mg
Description: Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
Study NCT06697782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
Study NCT06712355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Solution for intravenous infusion
Study NCT06712355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Concentrate for solution for intravenous infusion
Study NCT06712355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Solution for infusion
Study NCT06712355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Solution for infusion
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine low dose formulation 1
Description: Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine low dose formulation 2
Description: Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine medium dose formulation 1
Description: Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine medium dose formulation 2
Description: Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine high dose formulation 1
Description: Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine high dose formulation 2
Description: Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT05587894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 5 days
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
Study NCT05587894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxlovid 10 days
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
Study NCT05587894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veklury
Description: Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Study NCT06257056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Laboratories Infinity™ implantable deep brain stimulation system
Description: Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
Study NCT05018702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: 1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Study NCT05492149 — intervention group
Intervention type: OTHER
Intervention: Performance follow-up
Description: Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.